Thermo Fisher Scientific Inc. (BMV:TMO)
Mexico · Delayed Price · Currency is MXN | Market Cap | 2.90T -4.0% |
| Revenue (ttm) | 815.38B +5.4% |
| Net Income | 123.54B +5.1% |
| EPS | 328.21 +6.7% |
| Shares Out | n/a |
| PE Ratio | 23.46 |
| Forward PE | 17.61 |
| Dividend | 32.22 (0.41%) |
| Ex-Dividend Date | Mar 13, 2026 |
| Volume | n/a |
| Average Volume | 420 |
| Open | 7,704.00 |
| Previous Close | 7,814.22 |
| Day's Range | 7,704.00 - 7,704.00 |
| 52-Week Range | 7,411.66 - 11,280.00 |
| Beta | 0.88 |
| RSI | 38.72 |
| Earnings Date | Apr 23, 2026 |
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and... [Read more]
Financial Performance
In 2025, Thermo Fisher Scientific's revenue was $44.56 billion, an increase of 3.91% compared to the previous year's $42.88 billion. Earnings were $6.70 billion, an increase of 5.82%.
Financial numbers in USD Financial StatementsNews
Thermo Fisher Scientific Announces Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0....
Thermo Fisher Scientific Transcript: AGM 2026
Shareholders elected all director nominees and ratified the auditor, but did not approve executive compensation. The company reported strong financials, highlighted its global reach, and outlined strategic priorities including AI adoption and continued productivity improvements.
Thermo Fisher Scientific Slides: FY 2026
Thermo Fisher Scientific has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
Thermo Fisher Scientific Transcript: Investor Day 2026
Positioned as an industry leader, the company targets 7% long-term organic revenue CAGR, driven by innovation, AI adoption, and disciplined capital deployment. Recent acquisitions and a robust commercial engine support share gains, with 2026 guidance of 3%–4% organic growth and 8%–10% EPS growth.
Thermo Fisher Scientific Slides: FY 2026
Thermo Fisher Scientific has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 20, 2026.
Thermo Fisher highlights growth outlook, long-term value creation
Thermo Fisher (TMO) Scientific hosted its Investor Day. Chairman and Chief Executive Officer Marc Casper and members of the senior leadership team highlighted the company’s industry leadership and the...
Thermo Fisher sees low-teens adjusted EPS growth over the long-term
The company said, “Thermo Fisher’s (TMO) proven growth strategy and disciplined approach to capital deployment position the company to deliver 7% organic revenue CAGR and low-teens adjusted EPS growth...
Thermo Fisher Scientific Highlights Industry Leadership, Growth Outlook and Long-Term Value Creation at 2026 Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and ...
Thermo Fisher Scientific's PPD Clinical Research Business Expands Bioanalytical Capabilities with New Laboratory in Gothenburg, Sweden
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, locat...
Amazon among seven added to Jefferies’ Franchise Picks list
Jefferies analysts added Amazon.com (AMZN), AppLovin (APP), Credo Technology (CRDO), McDonald’s (MCD), RadNet (RDNT), Thermo Fisher (TMO) and UL Solutions (ULS) to Jefferies’ Franchise Picks list, whi...
Thermo Fisher resumed with a Sector Perform at RBC Capital
RBC Capital resumed coverage of Thermo Fisher (TMO) with a Sector Perform rating and $490 price target The rating balances confidence in end market improvement with the structural risks to…
Nuvation Bio collaborating with Thermo Fisher to manufacture Ibtrozi in NSCLC
Nuvation Bio (NUVB) announced the completion of process tech transfer and product introduction to Thermo Fisher (TMO) for Ibtrozi – taletrectinib – to treat advanced or metastatic ROS1-positive non-sm...
Nalgene Outdoor Introduces Fresh Flow™ Straw Bottle
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sac...
Thermo Fisher Scientific Proxy statement: Proxy filing
Thermo Fisher Scientific filed a proxy statement on May 11, 2026, providing details for shareholder voting and corporate governance matters.
Thermo Fisher Scientific's Clinical Research Business Named a Leader Among CROs in 2026 ISG Provider Lens™ Report for Use of AI in Clinical Trials
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider L...
Thermo Fisher Scientific Unveils an Integrated Platform to Advance Scalable Cell Therapy Manufacturing
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform ...
Thermo Fisher Scientific Opens U.S. Flagship Bioprocess Design Center to Accelerate the Delivery of Life-changing Therapies
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company's Pl...
Thermo Fisher Scientific to Host Investor Day
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in...
Thermo Fisher to Sell Microbiology Business to Astorg
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher price target lowered to $620 from $670 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh lowered the firm’s price target on Thermo Fisher (TMO) to $620 from $670 and keeps an Overweight rating on the shares. Investors “were clearly looking…
Thermo Fisher to sell microbiology business to Astorg for $1.075B
Thermo Fisher (TMO) Scientific has signed a definitive agreement to sell its microbiology business to Astorg for consideration of approximately $1.075B, consisting of cash and a $50M seller note. The…
Thermo Fisher to sell its microbiology business to Astorg for about $1.08 billion
Thermo Fisher Scientific said on Monday it has agreed to sell its microbiology business to a pan-European private equity firm Astorg for about $1.08 billion, consisting of cash and a $50...
Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology busi...
Thermo Fisher price target lowered to $600 from $700 at Stifel
Stifel analyst Daniel Arias lowered the firm’s price target on Thermo Fisher (TMO) to $600 from $700 and keeps a Buy rating on the shares.
Thermo Fisher price target lowered to $639 from $653 at Baird
Baird analyst Catherine Ramsey Schulte lowered the firm’s price target on Thermo Fisher (TMO) to $639 from $653 and keeps an Outperform rating on the shares. The firm updated its…